These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28521029)

  • 1. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
    Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
    Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
    Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers.
    Mizutani H; Nakane S; Ikeda T; Nakamura H; Takamatsu K; Makino K; Tawara N; Mukaino A; Watari M; Matsui H; Mukasa A; Ando Y
    Ann Clin Transl Neurol; 2018 Dec; 5(12):1611-1616. PubMed ID: 30564626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.
    Kyrtsonis MC; Sarris K; Koulieris E; Maltezas D; Nikolaou E; Angelopoulou MK; Bartzis V; Tzenou T; Dimou M; Siakandaris MP; Viniou NA; Sachanas S; Kalpadakis C; Sfikakis PP; Pangalis GA; Panayiotidis P
    Biomed Res Int; 2014; 2014():159632. PubMed ID: 25162001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
    Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
    Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features of Isoforms of Human Soluble TACI.
    Fichtner ML; Rübsamen H; Smolle M; Schaller J; Feederle R; Bültmann A; Kümpfel T; Schneider P; Thaler FS; Meinl E
    J Immunol; 2023 Jul; 211(2):199-208. PubMed ID: 37272840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
    Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
    Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
    Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
    Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
    Hottinger AF; Iwamoto FM; Karimi S; Riedel E; Dantis J; Park J; Panageas KS; Lassman AB; Abrey LE; Fleisher M; Holland EC; DeAngelis LM; Hormigo A
    Ann Neurol; 2011 Jul; 70(1):163-9. PubMed ID: 21391238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APRIL and sTACI could be predictors of multiorgan dysfunction syndrome in sepsis.
    Lendak DF; Mihajlović DM; Novakov-Mikić AS; Boban JM; Ubavić M; Brkić SV
    Virulence; 2018 Dec; 9(1):946-953. PubMed ID: 29781374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.